Thromboembolic Complications in COVID-19 Patients in Intensive Care Unit

NCT06037707 | Completed

• 1 other identifier: DerinceTRH-07
• Study Type: observational
• Target: 484
• Locations: 1 country
• Sites: 1

Brief Summary

The present study aims to determine frequency of thromboembolic complications and the underlying causes of this complication of the patients who admitted to the intensive care unit diagnosed with COVID-19.

Conditions

COVID-19-Associated Thromboembolism

Keywords

COVID-19; thromboembolism; Variants of COVID-19

Outcome Measures

Primary Outcomes (1)

• Rate of thromboembolic complications among patients who effected from different variants of COVID-19 Disease

  Both arterial and venous thromboembolic events were detected

  During the entire intensive care stay up to 1 day

Secondary Outcomes (3)

• Rate of thromboembolic complications of COVID-19 disease in critically ill patients

  During the entire intensive care stay up to 1 day

• Rate of thromboembolic complications according to anticoagulant therapy

  During the entire intensive care stay up to 1 day

• What is the rate of thromboembolism according to the comorbidities

  During the entire intensive care stay up to 1 day

Study Arms (4)

Ancestral variant

Ancestral variant is the first subtype of SARS CoV-2 virus which is the agent of first COVID-19 infection in Wuhan. Thromboembolic complications of this group were detected among patients which were infected with ancestral variant of COVID-19

Delta Variant

Delta variant is the subtype of SARS CoV-2 virus which is first COVID-19 subtype identified in India. Thromboembolic complications of this group were detected among patients which were infected with delta variant of COVID-19

Alpha variant

Alpha variant is the subtype of SARS CoV-2 virus which is first identified COVID-19 subtype in United Kingdom. Thromboembolic complications of this group were detected among patients which were infected with alpha variant of COVID-19

Other variants

Other variants is the subtype of SARS CoV-2 virus which were identified in Brazil, South Africa..etc. Thromboembolic complications of this group were detected among patients which were infected with alpha variant of COVID-19

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Study Population of the present study is all of the patients diagnosed with COVID-19 and admitted to the intensive care units at Derince Training and Research Hospital at the time of between 1-March-2020 and 31-December-2021in

You may qualify if:

• Patients who were infected with COVID-19 and admitted to the intensive care unit between the time of March 2020-December 2021

You may not qualify if:

• who is under 18 years old.

Sponsors & Collaborators

• Ayse Zeynep Turan: lead

Study Sites (1)

Derince Research and Training Hospital

Kocaeli, Derince, 41900, Turkey (Türkiye)

Location

MeSH Terms

Conditions

COVID-19; Thromboembolism

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Berna Karakoyun Lacin, Prof.

  Health and Science University Hamidiye Institute of Health Sciences

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principle Investigator

Study Record Dates

• First Submitted: September 1, 2023
• First Posted: September 14, 2023
• Study Start: January 1, 2022
• Primary Completion: June 30, 2022
• Study Completion: August 30, 2023
• Last Updated: January 25, 2024

Record last verified: 2024-01

Locations

TU (1)